Changed immune cells given in the brain for glioblastoma or astrocytoma that has come back
Original title: Intracranial Genetically Modified Immune Cells (TGFβR2KO/IL13Rα2 CAR T-Cells) for the Treatment of Recurrent or Progressive Glioblastoma or Grade 3 or 4 IDH-Mutant Astrocytoma
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is an early safety test in people.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This study tests a treatment made from a person's own immune cells, put right inside the skull.
Who this trial is for. This trial is for people with glioblastoma: A glioma that is given grade 4. Grade 4 is the highest grade there is. The tumor grows fast. Treatment usually starts soon after it is found. It often means surgery, and then radiation and chemotherapy. See the glossary, or grade 3 or 4 IDH gene change: A small change in a tumor's IDH gene. It is the first thing your team looks at when naming an adult glioma, and it can affect which treatments are offered. Your pathology report says whether your tumor has it. See the glossary astrocytoma, that has come back or is getting worse. It tests CAR T cells made from the person's own blood cells and given inside the skull.
Where it stands. This is a phase 1 trial. It is checking safety, side effects, and the best dose to give. The trial has not reported results. We do not know yet if this helps people live longer or feel better.
What this means, and what it doesn't
What it could mean: Doctors are still learning if this is safe and how much to give. Someone whose tumor fits this picture could ask their care team about it. The care team can say if it makes sense to look into.
What it doesn't mean: A trial is a test, not a proven treatment. Being in one is not a guarantee that you will benefit. This is not a promise of a cure.
Source: ClinicalTrials.gov, October 22, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.